Frédéric Revah, speaking at World Orphan Drug Congress 2011

Frédéric Revah,
CEO
Genethon

Frédéric Revah joined Genethon as CEO in January 2010 and bringing over 20 years' experience in the pharmaceutical and biotech industries as well as academic research.
Immediately prior to joining Genethon in January 2010, he had been Chief Executive Officer of the oncology start-up Sepal Pharma since 2008. Before that, he had served as Vice President Drug Discovery, and Chief Scientific Officer at the biotech company Cerep since 1999 and Chief Executive Officer of its oncology subsidiary. At Cerep, he had worldwide responsibility for the company's R&D platform (250 researchers and technicians). Prior to his time at Cerep, he was Head of the Gene Therapy for Central Nervous System Diseases Department and of the Neurochemistry Department at Rhône Poulenc Rorer (now Sanofi) from 1992 to 1998.
Frédéric Revah started his career as an associate staff researcher at the Pasteur Institute (from 1990 to 1992). He obtained his Ph.D. at the Pasteur Institute in 1991 and is a graduate of the Ecole Polytechnique engineering school (1985).

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

12.30pm

The growing role of patient groups taking charge of all parts of the value chain

How are the traditional strengths of patient groups developing in the orphan drug arena?
Non-profit Pharma Company - how can patient groups gain the funding to move into rare disease R&D?
What have been the lessons learnt from undertaking multi-centre clinical trials?
What should be the future direction of patient groups to advance treatment development?

Frédéric Revah,

CEO,
Genethon

4.45pm

Panel discussion: From big pharma to niche specialist: lessons learned from rare disease collaborations

What have been the strategies of big pharma and how are they engaging in partnerships?
How are drug candidates selected for backing outside of the internal research walls?
What are the future responsibilities of patient groups within research alliances?
How do biotechs and specialised pharma companies assess potential partnering?

Dr. Alvin Shih,

Director, Orphan and Genetic Diseases,
Pfizer

Philippe Monteyne,

SVP, Head of Development & CMO,
GSK

Jörn Aldag,

CEO,
Amsterdam Molecular Therapeutics

Frédéric Revah,

CEO,
Genethon

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor